✨
AI Summary
- Novo Nordisk leads in oral obesity drugs; GSK strengthens its strategy.
- Pfizer's outlook improves due to Vyndamax settlements; China leads drug launches.
- J&J abandons two lymphoma CAR-T therapies.
Citeline Podcasts